Karyopharm Therapeutics (NASDAQ:KPTI) Given New $7.00 Price Target at HC Wainwright

Karyopharm Therapeutics (NASDAQ:KPTI) had its price target cut by HC Wainwright from $8.00 to $7.00 in a research note issued to investors on Friday morning, Benzinga reports. They currently have a buy rating on the stock.

Karyopharm Therapeutics Stock Down 10.8 %

Karyopharm Therapeutics stock opened at $0.87 on Friday. Karyopharm Therapeutics has a 52 week low of $0.62 and a 52 week high of $1.95. The firm’s 50-day simple moving average is $1.04 and its 200 day simple moving average is $1.10. The firm has a market capitalization of $108.12 million, a PE ratio of -0.68 and a beta of 0.25.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.01. The business had revenue of $33.13 million during the quarter, compared to analysts’ expectations of $35.02 million. On average, research analysts expect that Karyopharm Therapeutics will post -1.25 EPS for the current fiscal year.

Insider Activity at Karyopharm Therapeutics

In related news, Director Deepika Pakianathan sold 204,394 shares of the business’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $0.95, for a total value of $194,174.30. Following the completion of the transaction, the director now owns 14,697 shares of the company’s stock, valued at approximately $13,962.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In the last quarter, insiders sold 1,282,902 shares of company stock valued at $1,244,993. 4.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Bleakley Financial Group LLC acquired a new position in shares of Karyopharm Therapeutics during the 4th quarter valued at about $33,000. Simplicity Solutions LLC purchased a new position in Karyopharm Therapeutics in the 4th quarter worth approximately $33,000. SG Americas Securities LLC boosted its holdings in Karyopharm Therapeutics by 295.0% in the 4th quarter. SG Americas Securities LLC now owns 73,430 shares of the company’s stock worth $64,000 after acquiring an additional 54,839 shares during the period. Simplicity Wealth LLC purchased a new position in Karyopharm Therapeutics in the 1st quarter worth approximately $66,000. Finally, Exchange Traded Concepts LLC boosted its stake in shares of Karyopharm Therapeutics by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 115,864 shares of the company’s stock valued at $100,000 after buying an additional 29,380 shares during the last quarter. Institutional investors and hedge funds own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).